---
review_canonical_topic: Rapamycin for Health & Longevity
prompt_version: 26.8.26
audit_date: 2026-0828-1620
audit_ai: Opus / Opus 5
audit_duration: "06:02"
audit_iterations: 13
---
# Audit: Rapamycin for Health & Longevity
Audit conducted on 28/08/2026 16:20 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5
[Iterations](#iterations)
## Summary
| Items | Count |
| ------------- | ---------------- |
| Total | 440 |
| Passed | 412 |
| Failed | 0 |
| N/A | 28 |
| **Pass Rate** | **100.00%** |
* Total = Passed + Failed + N/A
* Pass Rate = Passed / (Passed + Failed) Γ 100
* N/A items are excluded from the pass rate calculation
## URL Verification
| Link | Loaded | Verified By | Match | Comment |
| ------------------------ | ------ | ----------- | ----- | ---------------- |
| [#272 β Rapamycin: potential longevity benefits, surge in popularity, unanswered questions, and more]() | π’ | d-browser | π’ | Page title matches the episode named in the link text. |
| [Ask the Author: Rapamycin's Role in Fighting Aging]() | π’ | d-fetch | π’ | d-browser returned "Access Denied"; d-fetch retrieved the genuine article, title matches. |
| [Results of a Crowdfunded One-Year Human Rapamycin Trial]() | π’ | d-browser | π’ | Article loads; byline is Josh Conway, 14 April 2025. |
| [Rapamycin]() | π’ | d-browser | π’ | Substantive topic article on rapamycin, not a directory entry. |
| [Rapamycin for longevity: opinion article]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [Sirolimus]() | π’ | d-browser | π’ | Primary dedicated Grokipedia page for the compound. |
| [Targeting ageing with rapamycin and its derivatives in humans: a systematic review]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [Meta-Analysis of 29 Experiments Evaluating the Effects of Rapamycin on Life Span in the Laboratory Mouse]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [Rapamycin, Not Metformin, Mirrors Dietary Restriction-Driven Lifespan Extension in Vertebrates: A Meta-Analysis]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [The effect of rapamycin and its analogues on age-related musculoskeletal diseases: a systematic review]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [rapamycin extended lifespan in genetically diverse mice even when started late in life]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [pooled patient-level data from 21 randomized trials]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [five-year randomized conversion trial]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [randomized, placebo-controlled trial in older adults]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [48-week trial]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [exercise trial]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [Phase 2a]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [phase 2b]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [The systematic review]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [randomized, placebo-controlled hand trial]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [the six-month everolimus pilot]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [the mouse meta-analysis]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [the dog trial]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [the human pilot in older adults]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [the preclinical meta-analysis]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [the mouse study]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [the mouse study of ovarian lifespan]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [pooled mouse data]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [the one long human trial]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [same 21-trial patient-level analysis]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [pooled analysis of seven randomized trials]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [hypercholesterolemia]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [a dosing study]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [the small pilot in healthy older adults at 1 mg daily]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [pooled randomized trials]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [a critical review of the randomized trials]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [a meta-analysis of conversion trials]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [a meta-analysis of 18 randomized trials]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [Estimated incidence is 4% to 11%]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [a systematic evaluation of 80 kidney-transplant recipients on sirolimus]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [A review of sirolimus adverse effects]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [The transplant meta-analysis]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [48-week trial]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [pooled transplant trials]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [systematic review of human aging trials]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [a retrospective cohort of 571 female kidney-transplant recipients]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [a systematic skin and mucosal evaluation of 80 kidney-transplant recipients on sirolimus]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [a case-control study]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [the 48-week healthy-adult trial]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [the healthy-adult trial]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [the long human trial]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [a real-world comparison]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [a randomized trial]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [the one long trial]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [NCT05836025]() | π’ | d-clinicaltrialsgov | π’ | NCT ID resolves; study title, phase and enrollment match the ER. |
| [NCT06658093]() | π’ | d-clinicaltrialsgov | π’ | NCT ID resolves; study title, phase and enrollment match the ER. |
| [NCT05949658]() | π’ | d-clinicaltrialsgov | π’ | NCT ID resolves; study title, phase and enrollment match the ER. |
| [NCT06727305]() | π’ | d-clinicaltrialsgov | π’ | NCT ID resolves; study title, phase and enrollment match the ER. |
| [NCT07191353]() | π’ | d-clinicaltrialsgov | π’ | NCT ID resolves; study title, phase and enrollment match the ER. |
| [exercise trial published in 2026]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [phase 3 infection trial]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
| [Mannick & Lamming, 2023]() | π’ | d-pubmed | π’ | PMID resolves; PubMed title matches the ER. |
## 1. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 1.1 | The focus of the document is to present the evidence for and against applying the intervention in question, with the stated goal | π’ | |
| 1.2 | The focus of the document is primarily on the effectiveness of the intervention, not cost. Cost is secondary at most | π’ | |
| 1.3 | The document does not jump to conclusions prematurely; it builds its case through evidence | π’ | |
| 1.4 | The tone of the document is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | π’ | |
| 1.5 | The document reads as a trusted, knowledgeable guide rather than a prescriptive doctor | π’ | |
| 1.6 | The document avoids language that implies medical or clinical advice | π’ | |
| 1.7 | The document "presents information" instead of "providing guidance", "recommending", or "advising" | π’ | |
| 1.8 | The document never addresses "the reader" directly β it presents evidence, not guidance | π’ | |
| 1.9 | Content is written in plain language, avoiding unnecessary medical jargon | π’ | |
| 1.10 | Information is presented in a concise and very compact manner | π’ | |
| 1.11 | When presenting multiple aspects, bullet points are used to enhance clarity and readability | π’ | |
| 1.12 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | π’ | |
| 1.13 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | π’ | |
| 1.14 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | π’ | |
| 1.15 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention's signal for the average person differs from its signal for this audience. | π’ | |
| 1.16 | The document's own voice frames usage in **longevity** terms, not "anti-aging" (e.g., "anti-aging clinics", "anti-aging community", "anti-aging medicine"). Proper names that contain "anti-aging" (e.g., "American Academy of Anti-Aging Medicine") are quoted verbatim. | π’ | No "anti-aging" framing appears anywhere in the document's own voice. |
| 1.17 | The document's own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., "oral medication" not "pill(s)"; "injection" not "shot"; "adverse event" not "bad reaction"). Direct quotes from sources are exempt. | π’ | |
## 2. Handling of Scientific Evidence
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 2.1 | When available, conclusions are based on high-quality human clinical trials, such as randomized controlled trials (RCTs) and meta-analyses. | π’ | |
| 2.2 | Observational studies, mechanistic data, and expert opinion from researchers and reputable physicians with practical experience, utilizing their books, blog posts, podcasts, and presentations, are used to provide context and fill in gaps where clinical data is lacking. | π’ | |
| 2.3 | It is stated clearly when high-quality evidence is conflicting or inconclusive (e.g., two large RCTs show different outcomes). | π’ | |
| 2.4 | If evidence is conflicting or inconclusive, different viewpoints or study outcomes are presented, and the potential reasons for the discrepancy, if known (e.g., differences in study design, population, dosage, or duration), are explained | π’ | |
| 2.5 | When a researcher's work is central to the topic, their primary sources (original publications, books, data) are examined directly β not solely through the lens of later critiques or dismissals | π’ | |
| 2.6 | Claims that prior research has been "debunked," "discredited," or "disproven" are treated as assertions that themselves require evidence. The critique is evaluated, not repeated as fact | π’ | |
| 2.7 | The document does not adopt any professional establishment's consensus position as the default truth. Mainstream and dissenting positions are both presented as claims supported (or not) by evidence. | π’ | |
| 2.8 | When the body of available evidence is produced primarily by parties with a direct financial interest in the intervention's adoption or rejection (e.g., professional associations whose members perform the procedure, pharmaceutical manufacturers, device makers), this conflict of interest is identified and named at first citation and again in the Conclusion. | π’ | AgelessRx, the Lifespan Research Institute, resTORbio and Novartis are named at line 150, flagged again at line 59, and restated in the Conclusion (line 548). |
| 2.9 | When competing interventions differ substantially in cost, the ER identifies whether institutional payers (insurers, national health systems) have a systematic financial incentive to favor one over the other, and notes this as a potential source of structural bias in guideline formation and research funding. | π’ | Line 150 notes that no patent holder and no insurer or national health system has an incentive to fund or pay for this use. |
| 2.10 | When a professional or advocacy organization is cited as a primary source of evidence or guidelines, the ER notes whether that organization's membership derives direct revenue from the conclusions it endorses β immediately adjacent to where the organization's position or advocacy is stated (not merely at its introduction or first mention), and again in the Conclusion. This applies symmetrically to all cited parties on all sides of the debate. | π’ | The Lifespan Research Institute's fundraising interest is disclosed adjacent to its item (line 59), at line 150, and in the Conclusion. |
| 2.11 | Content is framed for the target audience (see 1.12), not as population-level outcomes. | π’ | |
| 2.12 | A finding attributed to a specific paper, or to a body of reviews (e.g., "Cochrane reviews of X showβ¦"), carries a link to that paper, or to one of those reviews. | π’ | |
## 3. General Formatting
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 3.1 | The document is output as a Markdown file (.md) | π’ | |
| 3.2 | All section headings use H2 formatting | π’ | |
| 3.3 | An extra blank line (two spaces + carriage return) appears before each section heading | π’ | |
| 3.4 | Every list (bulleted or numbered) is preceded by a blank line | π’ | |
| 3.5 | New lines are created using two spaces and a carriage return | π’ | |
| 3.6 | Emojis are always encoded using the corresponding Unicode, not the short code. e.g., π’ (Unicode) instead of ":green_circle:", π΄ (Unicode) instead of ":red_circle:" | π’ | |
| 3.7 | The document contains no unrendered AI-internal markup (e.g., citation tokens, reference IDs, source tags, or debug metadata) | π’ | |
| 3.8 | Scientific nomenclature and technical symbols follow their field conventions everywhere in the document β in frontmatter fields, headings, body text, tables, and captions. | π’ | |
| 3.9 | These conventions override "Chicago Manual of Style" (CMS) where they conflict | π’ | |
| 3.10 | Binomial species names: genus is capitalized, species epithet is lowercase. Examples: "Lactobacillus acidophilus" not "Lactobacillus Acidophilus"; "Ginkgo biloba"; "Rhodiola rosea"; "Tribulus terrestris"; "Bifidobacterium lactis"; "Curcuma longa". This applies inside longer phrases too ("Ginkgo biloba extract", "Withania somnifera root"). Binomials SHOULD be italicized in body text when context allows (*Lactobacillus acidophilus*); frontmatter and headings stay plain. | π’ | |
| 3.11 | Trinomial/subspecies names: genus capitalized; species and subspecies epithets lowercase. Example: "Bifidobacterium animalis subsp. lactis". | π’ | |
| 3.12 | Stereochemistry prefixes: `L-`, `D-`, `l-`, `d-`, `cis-`, `trans-`, `R-`, `S-` keep their conventional case and stay hyphenated to the next token. The token following a capitalized prefix is title-cased per CMS ("L-Theanine", "D-Ribose", "cis-9, trans-11 CLA"). | π’ | |
| 3.13 | Gene and protein symbols: follow field convention, not CMS. Examples: "FOXO4", "mTOR", "p53", "HIF-1Ξ±", "NF-ΞΊB", "IGF-1". Human gene symbols are all-caps; mouse gene symbols are title-case with the rest lowercase ("Foxo4"). | π’ | |
| 3.14 | Chemical compound names and IUPAC forms: keep hyphens, numeric locants, and lowercase elements as written ("N-acetylcysteine" in body text, "N-Acetylcysteine" only if it is the canonical_name/short_topic where CMS title-case applies to the word after the prefix). | π’ | |
| 3.15 | Every word count in this document excludes HTML comments. They record provenance for the auditor, not content for the reader, and the search statements required in Sections 9β12 are on their own longer than the annotation limits those sections set. | π’ | All search statements sit in HTML comments on their own lines and are excluded from every word count. |
## 4. Glossary Enforcement
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 4.1 | Every medical acronym (e.g., DASH, SGLT2, mTOR, AMPK, BUN, CMP, eGFR) includes a plain-language explanation at first use | π’ | |
| 4.2 | Every drug class name (e.g., ARB, ACE inhibitor, SGLT2 inhibitor) includes a plain-language explanation at first use | π’ | |
| 4.3 | Every biological pathway name (e.g., RAAS, PPAR-Ξ³, mTOR, AMPK) includes a plain-language explanation at first use | π’ | |
| 4.4 | Every statistical term (e.g., CI, HR, RR, OR, NNT) includes a plain-language explanation at first use | π’ | |
| 4.5 | Every exercise and nutrition term (e.g., Zone 2, DASH, HIIT) includes a plain-language explanation at first use | π’ | |
| 4.6 | Every uncommon medical condition or symptom name (e.g., angioedema, rhabdomyolysis, hyperkalemia, orthostatic hypotension) includes a plain-language explanation at first use | π’ | |
| 4.7 | Every enzyme and genetic polymorphism (e.g., CYP2C9, UGT1A3, ABCB1, APOE4, MTHFR, and COMT) includes a very short explanation of what the enzyme or gene does at first use | π’ | |
| 4.8 | Clinical trial names and brand/product names are NOT given glossary explanations (they are exempt) | π’ | |
| 4.9 | Plain-language explanations are brief and in parentheses | π’ | |
| 4.10 | First use is determined by reading order (top to bottom); the explanation appears where the term is first encountered, starting at the motivation section. | π’ | |
| 4.11 | Frontmatter, title, and "Also known as:" line are exempt from glossary rules | π’ | |
| 4.12 | If an acronym first appears inside a table cell, the expansion is provided in a "Context/Notes" column, not crowding the table cell itself | π’ | |
## 5. Hyperlinks
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 5.1 | All links are syntactically valid (proper URL format) | π’ | |
| 5.2 | All links use standard Markdown syntax: "[text](URL)" | π’ | |
| 5.3 | No URLs appear to have been constructed by guessing or interpolating from memory | π’ | |
| 5.4 | All pipe characters "\|" in markdown link text are replaced with an en-dash "β" | π’ | |
| 5.5 | PubMed links use the format "https://pubmed.ncbi.nlm.nih.gov/PMID/" β not publisher sites (e.g., not ahajournals.org, sciencedirect.com, wiley.com) | π’ | |
| 5.6 | No link points to PubMed Central β an article available on PMC is linked by its PubMed ID in the format "https://pubmed.ncbi.nlm.nih.gov/PMID/" | π’ | |
| 5.7 | ClinicalTrials.gov links use the format "https://clinicaltrials.gov/study/" | π’ | |
| 5.8 | DOI links use the format "https://doi.org/" | π’ | No DOI links are used; all citations resolve through PubMed or ClinicalTrials.gov. |
| 5.9 | No link points directly to a PDF file. A URL whose path ends in ".pdf" (optionally followed by a query string or fragment) or that serves "application/pdf" is a FAIL. Links must resolve to an HTML landing or abstract page (e.g., the PubMed, DOI, or publisher article page), never a raw PDF download. | π’ | |
| 5.10 | Each URL retrieves the genuine target page | π’ | All 63 links retrieved the genuine target page (see URL Verification). |
| 5.11 | The page at each URL contains content matching the link's annotation in the ER (the page is about the cited topic; the article/resource title matches) | π’ | Every retrieved page matches its annotation (see URL Verification). |
| 5.12 | Link text that describes a specific study, trial, or finding resolves to that study β not to a reference work, monograph, database entry, or review that merely mentions it. Link text pointing to such a secondary source names it as one (e.g. "a drug monograph", "a systematic review"), never as the primary finding. | π’ | Secondary sources are named as such ("a critical review of the randomized trials", "The systematic review", "A review of sirolimus adverse effects", "the preclinical meta-analysis"). |
| 5.13 | No link points to a web archive or cache β web.archive.org, archive.today/archive.ph, or a search-engine cache. If the live URL cannot be retrieved, the link is REMOVED rather than replaced with an archived copy. | π’ | |
## 6. Frontmatter - Metadata
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 6.1 | The document starts with a frontmatter section containing metadata about the document | π’ | |
| 6.2 | The initial topic used in the prompt to create the review is stated as 'initial_topic: "[initial_topic]"' | π’ | |
| 6.3 | If the [initial_topic] of the evidence review is just a name of a single intervention or a list of interventions (e.g., "Metformin", "Resveratrol & NMN"), the [topic] is stated as "topic: "[initial_topic] for Health & Longevity"" | N/A | [initial_topic] is not a bare intervention name, so this expansion rule does not apply. |
| 6.4 | If the [initial_topic] of the evidence review is of the form "[intervention(s)] : [goal]", the [topic] is stated as "topic: "[intervention(s)] to/for/as [goal]" using a fitting preposition (e.g., "Metformin : Skin Rejuvenation" β "Metformin for Skin Rejuvenation") | N/A | [initial_topic] is not of the form "[intervention(s)] : [goal]". |
| 6.5 | Otherwise [topic] is stated as 'topic: "[initial_topic]"' | π’ | |
| 6.6 | The [topic] of the evidence review is normalized to the form of "[intervention] to/for/as [goal]" | π’ | |
| 6.7 | The [intervention] part of the [topic] is stated as "intervention: [intervention]" | π’ | |
| 6.8 | The [goal] part of the [topic] is stripped of any preposition and wordiness and stated as "goal: [goal]", e.g., "to Optimize Immune Function" β "Optimize Immune Function", "for Skin Rejuvenation" β "Skin Rejuvenation", "as a Longevity Intervention" β "Longevity" | π’ | |
| 6.9 | The [canonical_name] is stated as "canonical_name: [intervention]" | π’ | |
| 6.10 | [canonical_name] must not expand [intervention] with synonyms, INN names, or alternate identifiers β even if known. Expansion belongs in alternate_names | π’ | |
| 6.11 | The [canonical_name] is simplified and compressed in a way that "and" is replaced by "&", prepositions and wordiness are removed where possible, but the essence is not altered (e.g., "Ivermectin and Mebendazole and Fenbendazole" β " Ivermectin, Mebendazole & Fenbendazole") | π’ | |
| 6.12 | [canonical_name] is capitalized following the "Chicago Manual of Style" rules, subject to the scientific-nomenclature overrides in section 3 | π’ | |
| 6.13 | The [intervention] is inspected and, if multiple variations, names, alternates, synonyms, or spellings exist, all of them, except [canonical_name], are stated as a comma-separated list as "alternate_names: [alternate_names]" (e.g., "Low Dose Naltrexone, LDN, Naltrexone") | π’ | |
| 6.14 | The [canonical_topic] is stated as "canonical_topic: 'Replacing [intervention] by [canonical_name] in [topic]' (e.g., "LDN to Optimize Immune Function" β "canonical_topic: Low-Dose Naltrexone to Optimize Immune Function") | π’ | |
| 6.15 | The [canonical_topic] is simplified in a way that prepositions and wordiness are removed where possible, but the essence is not altered (e.g., "Using a combination of Ivermectin, Mebendazole & Fenbendazole to Fight Cancer" β "Ivermectin, Mebendazole & Fenbendazole to Fight Cancer") | π’ | |
| 6.16 | [canonical_topic] is capitalized following the "Chicago Manual of Style" rules, subject to the scientific-nomenclature overrides in section 3 | π’ | |
| 6.17 | If [goal] is "Health & Longevity" [short_goal] is stated as "short_goal: Longevity". | π’ | |
| 6.18 | If [goal] is not "Health & Longevity", a one keyword form of [goal] containing no verb, is stated as "short_goal: [short_goal]" (e.g., "Optimize Immune Function" β "Immune", "Improve Insulin Sensitivity" β "Insulin", "Support Cardiovascular Health" β "Cardiovascular", "Reduce Inflammation" β "Inflammation", "Skin Rejuvenation" β "Skin") | N/A | [goal] is "Health & Longevity", so rule 6.17 applies instead. |
| 6.19 | If [short_goal] is "Longevity" [short_topic] is stated as "short_topic: [canonical_name]" | π’ | |
| 6.20 | If [short_goal] is not "Longevity" [short_topic] is stated as "short_topic: [canonical_name] ([short_goal])" (e.g., "Low-Dose Naltrexone (Immune)", "Metformin (Cancer)") | N/A | [short_goal] is "Longevity", so rule 6.19 applies instead. |
| 6.21 | [short_topic] is capitalized following the "Chicago Manual of Style" rules, subject to the scientific-nomenclature overrides in rule section 3 | π’ | |
| 6.22 | [short_topic_lc] is stated as "short_topic_lc: ``{[short_topic] converted to lowercase, then spaces and dashes are replaced with underscores, then any remaining non-alphanumeric, non-underscore characters are removed, then any consecutive underscores are collapsed to a single underscore, then any leading or trailing underscores are stripped}`` " (e.g., "Low-Dose Naltrexone (Immune)" β "low_dose_naltrexone_immune", "L-Theanine" β "l_theanine", "EPA & DHA" β "epa_dha", "Vitamin K2 (MK-4 & MK-7)" β "vitamin_k2_mk_4_mk_7")) | π’ | |
| 6.23 | Version of the AI4L.md file used to create the document is stated as "prompt_version: [Version of AI4L.md]" | π’ | |
| 6.24 | Creation date and time of the document is stated as "creation_date: [YYYY-MMDD-HHMM]" (e.g., 2026-0501-1430) | π’ | |
| 6.25 | The nickname of the AI used to create the document is stated as "creator_ai_nickname: [creator_ai_nickname]" | π’ | |
| 6.26 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | π’ | |
| 6.27 | The full name of the AI used to create the document is stated as "creator_ai_fullname: [creator_ai_fullname]" | π’ | |
| 6.28 | The full name of the AI consists of the [creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | π’ | |
| 6.29 | The knowledge cutoff of the AI is stated as "knowledge_cutoff: [knowledge_cutoff]" | π’ | |
| 6.30 | The filename of the document is stated as "filename: [short_topic_lc]_[creation_date]_[creator_ai_nickname]_ER.md" | π’ | |
| 6.31 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | π’ | Only initial_topic, topic and duration are quoted; the first two are quoted as rules 6.2-6.5 require, duration contains a colon. |
## 7. Title
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 7.1 | Title is formatted as H1 | π’ | |
| 7.2 | Title is stated as [canonical_topic] | π’ | |
| 7.3 | Title is followed by a line stating `\` | π’ | |
| 7.4 | A next line follows, stating "Evidence Review created on [creation_date reformatted as MM/DD/YYYY] using \[AI4L]\(https://github.com/forever-healthy/AI4L) / [creator_ai_fullname]" | π’ | |
| 7.5 | If [alternate_names] exist, a line follows stating "**Also known as:** [alternate_names]" and the line is preceded by a blank line | π’ | |
## 8. Sections
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 8.1 | Document is structured in sections | π’ | |
| 8.2 | All sections present in the order given below | π’ | |
| 8.3 | Motivation | π’ | |
| 8.4 | Recommended Reading | π’ | |
| 8.5 | Grokipedia | π’ | |
| 8.6 | Examine | π’ | |
| 8.7 | ConsumerLab | π’ | |
| 8.8 | Systematic Reviews | π’ | |
| 8.9 | Mechanism of Action | π’ | |
| 8.10 | Historical Context & Evolution | π’ | |
| 8.11 | Expected Benefits | π’ | |
| 8.12 | Benefit-Modifying Factors | π’ | |
| 8.13 | Potential Risks & Side Effects | π’ | |
| 8.14 | Risk-Modifying Factors | π’ | |
| 8.15 | Key Interactions & Contraindications | π’ | |
| 8.16 | Risk Mitigation Strategies | π’ | |
| 8.17 | Therapeutic Protocol | π’ | |
| 8.18 | Discontinuation & Cycling | π’ | |
| 8.19 | Sourcing and Quality | π’ | |
| 8.20 | Practical Considerations | π’ | |
| 8.21 | Interaction with Foundational Habits | π’ | |
| 8.22 | Monitoring Protocol & Defining Success | π’ | |
| 8.23 | Emerging Research | π’ | |
| 8.24 | Conclusion | π’ | |
## 9. Recommended Reading
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 9.1 | Section starts with a one-sentence description of its contents | π’ | |
| 9.2 | A real-time search was performed for the topic for content that is directly relevant and gives a "high-level" overview of the topic: they discuss the specific topic by name, or its primary mechanism/therapeutic category, in substantial depth | π’ | |
| 9.3 | A statement by the author about the search is placed inside an HTML comment | π’ | |
| 9.4 | Content is of eligible type: blog posts, podcast episodes, video presentations, YouTube lectures, expert commentary, and qualifying academic articles (primary research, narrative reviews, editorials β NOT systematic reviews or meta-analyses) | π’ | |
| 9.5 | Content from the following experts is prioritized (where directly relevant content exists): Rhonda Patrick (foundmyfitness.com), Peter Attia (peterattiamd.com), Andrew Huberman (hubermanlab.com), Chris Kresser (chriskresser.com), Life Extension Magazine (lifeextension.com), Lifespan.io (lifespan.io) | π’ | Peter Attia, Life Extension, Lifespan.io and FoundMyFitness (Rhonda Patrick) are represented; the Huberman and Kresser absences were independently checked by web and platform search and match the ER's explanation. |
| 9.6 | The following are excluded: Grokipedia, Examine, ConsumerLab content (these have their own dedicated sections) | π’ | |
| 9.7 | The following are excluded: Systematic reviews, meta-analyses (these belong in the Systematic Reviews section) | π’ | |
| 9.8 | The following are excluded: Encyclopedias, wikis, AI-generated reference sites (e.g., Wikipedia) | π’ | |
| 9.9 | The following are excluded: Forums, Reddit threads, community discussion boards, Q&A sites, social media posts | π’ | |
| 9.10 | The following are excluded: All mainstream media - TV, print, and radio, including their related online content (e.g., MSNBC, FOX, NYT, WAPO, ...) | π’ | |
| 9.11 | The following are excluded: entries in a database, registry, or directory β pages that catalogue a compound or intervention rather than discuss it | π’ | |
| 9.12 | Up to 5 items are listed. Every item independently satisfies 9.2 and 9.4 and falls outside the exclusions in 9.6β9.11; neither reaching the count nor an item's presence on a priority platform is itself a justification for inclusion | π’ | |
| 9.13 | Where fewer than five qualify, fewer are listed, with a brief explanation visible to the user of why | N/A | Five qualifying items are listed, so the fewer-than-five case does not arise. |
| 9.14 | No more than one item per expert, publication, or organization is included (no duplicates from the same source) | π’ | |
| 9.15 | Items are presented in a bulleted list, not a numbered list | π’ | |
| 9.16 | The title of each item is linked to the actual article | π’ | |
| 9.17 | The title is shown in plain text, not bold text | π’ | |
| 9.18 | The title is followed by a reference to the author of the item in the form of " - " | π’ | |
| 9.19 | ONLY if no author is available, the publication is used in the form of " - " | π’ | Used only for the Life Extension interview and the FoundMyFitness topic page, neither of which carries a byline. |
| 9.20 | If the item is a scientific paper, the publication year of the paper is included in the form of " - , " | π’ | |
| 9.21 | If the item is a scientific paper, the author attribution is an actual person's name or " et al.", not a journal name, article type descriptor, or organization name | π’ | |
| 9.22 | Each link is verified per Section 5 (Loading, Content, Semantics) | π’ | |
| 9.23 | Each item has a 1β2 sentence annotation in a new paragraph explaining its specific value | π’ | |
| 9.24 | When an item qualifies via mechanism or therapeutic category (9.2) rather than naming the intervention, the annotation names the shared mechanism or target explicitly (e.g. "the ghrelin receptor GHSR-1a, which GHRP-2 activates"). | N/A | All five items name rapamycin directly; none qualifies via mechanism or therapeutic category alone. |
| 9.25 | The new paragraph for the annotation is separated from the title by a blank line | π’ | |
| 9.26 | If content from one or more of the priority experts could not be found, a brief note, visible to the user, at the end of the section, explains why | π’ | |
| 9.27 | If fewer than 5 high-quality sources could be found, a brief note, visible to the user, explains this, and the list is not padded with marginally relevant content | N/A | Five high-quality sources were found. |
| 9.28 | Each annotation is at most 35 words | π’ | |
## 10. Grokipedia
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 10.1 | grokipedia.com was searched directly for the intervention using the browser tool | π’ | |
| 10.2 | A statement by the author about the search is placed inside an HTML comment | π’ | |
| 10.3 | An independent direct search of grokipedia.com by the auditor using the browser tool has confirmed the presence/absence of the intervention | π’ | Auditor searched grokipedia.com directly: the Sirolimus page is the primary dedicated entry (391 results, Sirolimus among them). |
| 10.4 | If an article exists, a link to the Grokipedia article is provided | π’ | |
| 10.5 | Suffixes in the link title, such as " β ", are removed from the link title | π’ | |
| 10.6 | If an article exists, the link is verified per Section 5 (Loading, Content, Semantics) and points to the site's primary, dedicated page for the intervention β not a filtered search view, research feed, subpage, or FAQ entry | π’ | |
| 10.7 | If an article exists, a 1β2 sentence annotation explains its specific value (in a new paragraph) | π’ | |
| 10.8 | If no article exists, this is explicitly stated | N/A | A Grokipedia article exists. |
| 10.9 | The section has no introductory text (besides the invisible HTML comment on the search) | π’ | |
| 10.10 | Each annotation is at most 35 words | π’ | |
## 11. Examine
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 11.1 | examine.com was searched directly for the intervention using the browser tool | π’ | |
| 11.2 | A statement by the author about the search is placed inside an HTML comment | π’ | |
| 11.3 | An independent direct search of examine.com by the auditor using the browser tool has confirmed the presence/absence of the intervention | π’ | Auditor searched examine.com directly: only the mTOR article and mTOR glossary entry are returned, confirming the ER. |
| 11.4 | If an article exists, a link to the Examine article is provided | N/A | No Examine article exists for rapamycin (auditor-confirmed). |
| 11.5 | The link title is the title of the Examine article | N/A | No Examine article link exists. |
| 11.6 | Suffixes in the link title, such as " β ", are removed from the link title | N/A | No Examine article link exists. |
| 11.7 | If an article exists, the link is verified per Section 5 (Loading, Content, Semantics) and points to the site's primary, dedicated page for the intervention β not a filtered search view, research feed, subpage, or FAQ entry | N/A | No Examine article link exists. |
| 11.8 | If an article exists, a 1β2 sentence annotation explains its specific value (in a new paragraph) | N/A | No Examine article exists. |
| 11.9 | If no article exists, this is explicitly stated | π’ | |
| 11.10 | If the intervention is a prescription drug and no article was found, this is noted with an explanation (e.g., "Examine.com does not typically cover prescription medications") | π’ | |
| 11.11 | The section has no introductory text (besides the invisible HTML comment on the search) | π’ | |
| 11.12 | Each annotation is at most 35 words | π’ | |
## 12. ConsumerLab
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 12.1 | consumerlab.com was searched directly for the intervention using the browser tool | π’ | |
| 12.2 | A statement by the author about the search is placed inside an HTML comment | π’ | |
| 12.3 | An independent direct search of consumerlab.com by the auditor using the browser tool has confirmed the presence/absence of the intervention | π’ | Auditor searched consumerlab.com directly: "Sorry, we didn't find any results for rapamycin", confirming the ER. |
| 12.4 | If an article exists, a link to the ConsumerLab article is provided | N/A | No ConsumerLab article exists for rapamycin (auditor-confirmed). |
| 12.5 | The link title is the title of the ConsumerLab article | N/A | No ConsumerLab article link exists. |
| 12.6 | Suffixes in the link title, such as " β ", are removed from the link title | N/A | No ConsumerLab article link exists. |
| 12.7 | If an article exists, the link is verified per Section 5 (Loading, Content, Semantics) and points to the site's primary, dedicated page for the intervention β not a filtered search view, research feed, subpage, or FAQ entry | N/A | No ConsumerLab article link exists. |
| 12.8 | If an article exists, a 1β2 sentence annotation explains its specific value (in a new paragraph) | N/A | No ConsumerLab article exists. |
| 12.9 | If no article exists, this is explicitly stated | π’ | |
| 12.10 | If the intervention is a prescription drug and no article was found, this is noted with an explanation (e.g., "ConsumerLab does not typically cover prescription medications") | π’ | |
| 12.11 | The section has no introductory text (besides the invisible HTML comment on the search) | π’ | |
| 12.12 | Each annotation is at most 35 words | π’ | |
## 13. Systematic Reviews
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 13.1 | A real-time PubMed search was performed for the intervention with "systematic review OR meta-analysis" | π’ | |
| 13.2 | Selection was prioritized by citation count (if available), study size, publication date (recent preferred), and relevance | π’ | Auditor's independent PubMed search returns the same core set; no more relevant systematic review or meta-analysis was overlooked. |
| 13.3 | If results exist, the section starts with a one-sentence description of its contents | π’ | |
| 13.4 | If NO results exist, the one-sentence description of the section's contents is omitted | N/A | Results exist, so the one-sentence description is required and present. |
| 13.5 | Up to 5 papers are listed | π’ | |
| 13.6 | Papers are presented in a bulleted list, not a numbered list | π’ | |
| 13.7 | All papers listed are relevant to the specific intervention being analyzed | π’ | |
| 13.8 | All papers listed are actually a systematic review or meta-analysis (not a narrative review or primary study) | π’ | |
| 13.9 | Where the intervention involves a trade-off, the listed papers include at least one on the claimed effect and at least one on the principal risk, cost, or forgone benefit, where the literature provides a systematic review or meta-analysis for each. Where it does not, the section states which is unrepresented. | π’ | |
| 13.10 | The title of each paper is linked to the paper's PubMed abstract page using the format "https://pubmed.ncbi.nlm.nih.gov/PMID/" | π’ | |
| 13.11 | No links point to publisher websites (e.g., ahajournals.org, sciencedirect.com, wiley.com) | π’ | |
| 13.12 | Each link is verified per Section 5 (Loading, Content, Semantics) | π’ | |
| 13.13 | The PubMed-retrieved title matches the title in the ER | π’ | All five PubMed-retrieved titles match the ER verbatim. |
| 13.14 | The title is shown in plain text, not bold text | π’ | |
| 13.15 | The title is followed by a reference to the author(s) and the publication year of the paper | π’ | |
| 13.16 | For single-author works "- , " is used | π’ | |
| 13.17 | For dual-author works "- & , " is used | N/A | No dual-author work is listed. |
| 13.18 | For works with more than two authors "- et al., " is used | π’ | |
| 13.19 | Each result has a 1β2 sentence annotation explaining its specific value (in a new paragraph) | π’ | |
| 13.20 | The new paragraph for the annotation is separated from the title by a blank line | π’ | |
| 13.21 | If no results exist, a statement follows the exact format: "No systematic reviews or meta-analyses for \ were found on PubMed as of \." | N/A | Systematic reviews and meta-analyses were found. |
| 13.22 | Each annotation is at most 25 words | π’ | |
## 14. Mechanism of Action
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 14.1 | The primary biological pathways or mechanisms are explained | π’ | |
| 14.2 | The explanation is appropriately concise but sufficient for a non-specialist to understand | π’ | |
| 14.3 | Relevant pathway names and acronyms are properly explained per glossary rules | π’ | |
| 14.4 | Where competing mechanistic explanations exist for or against the intervention, both are presented | π’ | |
| 14.5 | If the intervention is a pharmacological compound, state its key pharmacological properties: half-life, selectivity, tissue distribution, and metabolism (primary pathway and relevant enzymes, e.g., CYP3A4) | π’ | |
| 14.6 | The mechanism section is 150β250 words | π’ | 245 words. |
## 15. Historical Context & Evolution
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 15.1 | The original intended use of the intervention is discussed | π’ | |
| 15.2 | The reasons it came to be considered for health optimization are explained | π’ | |
| 15.3 | When historical research is discussed, the actual findings are described β not just the reception or critique of the research | π’ | |
| 15.4 | Historical research is not dismissed with labels such as "debunked," "discredited," or "disproven" β the evidence for and against is presented, and the reader can assess the current standing | π’ | |
| 15.5 | When describing the evolution of scientific opinion, the section does not frame the current consensus as the final word β it notes what changed and why, including what new evidence emerged on either side | π’ | |
| 15.6 | If the section does not apply to the intervention, this is briefly noted | N/A | The section applies to rapamycin and is written in full. |
| 15.7 | The historical context is 150β250 words | π’ | 249 words. |
## 16. Expected Benefits
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 16.1 | All major known benefits of the intervention are addressed (no significant omissions) | π’ | Cross-checked against the Lee 2024 systematic review: its cardiovascular signal is the everolimus pulmonary-hypertension pilot, which the ER lists. |
| 16.2 | Each item is a distinct outcome. The same outcome is not restated at a different granularity, split by population or endpoint, or repeated under another evidence level; where two items share a mechanism and an endpoint, they are merged. | π’ | |
| 16.3 | Content is framed for the target audience (see 1.12), not as population-level outcomes. | π’ | |
| 16.4 | A dedicated search for the intervention's complete benefit profile was performed using clinical and expert sources before writing this section. A statement by the author about the search is placed inside an HTML comment at the start of the section. | π’ | Search statement at line 146. |
| 16.5 | Each item is assigned a "Level of Evidence" grade | π’ | |
| 16.6 | Only the following four levels are used exactly: High, Medium, Low, Speculative | π’ | |
| 16.7 | No hybrid or intermediate levels are used (e.g., no "Low-Medium" or "Medium-High") | π’ | |
| 16.8 | Items are grouped by evidence level | π’ | |
| 16.9 | The groups are presented in the order: High, Medium, Low, Speculative | π’ | |
| 16.10 | The group High is presented as "### High π© π© π©" | π’ | |
| 16.11 | The group Medium is presented as "### Medium π© π©" | π’ | |
| 16.12 | The group Low is presented as "### Low π©" | π’ | |
| 16.13 | The group Speculative is presented as "### Speculative π¨" | π’ | |
| 16.14 | The actual item titles are presented in H4 | π’ | |
| 16.15 | The actual item levels are not shown on a per-item basis | π’ | |
| 16.16 | Each item includes an annotation paragraph between the H4 title and the Magnitude line | π’ | |
| 16.17 | The annotation is 2β5 sentences and at most 90 words for High and Medium, 50 for Low, 35 for Speculative, covering: what the benefit is, the proposed mechanism (if relevant), the evidence basis (e.g., "meta-analysis of 20 RCTs", "large observational cohort"), and any contextual nuance (limitations, population specifics, conflicting findings) | π’ | |
| 16.18 | The annotation is preceded and followed by a blank line | π’ | |
| 16.19 | Speculative items also include an annotation; if no controlled studies exist, it notes the basis is mechanistic or anecdotal only | π’ | |
| 16.20 | Where evidence is directly conflicted, a "β οΈ Conflicted" flag appears directly after the item name in the title (not in the annotation) | π’ | |
| 16.21 | Conflicted evidence is explained in the annotation text. The annotation's last sentence states the net reading of the conflict in one sentence. | π’ | |
| 16.22 | Each item (except Speculative) includes a "**Magnitude:** " line giving the first of the following that the literature supports: a. an actual outcome as a figure β effect size, absolute or relative risk, prevalence, score change, or change per unit of exposure; b. the direction plus the conditions under which it holds (e.g., "prevalence rises steeply above 2 mg/L"), together with a statement that the literature report no outcome figure. | π’ | |
| 16.23 | If the literature supports neither, the line begins exactly "**Magnitude:** Not quantified in available studies." and continues with one sentence stating why the literature gives none (e.g., no controlled trial has measured this outcome; only case reports exist) | N/A | Every non-Speculative item satisfies 16.22a or 16.22b, so the fallback line is not needed. |
| 16.24 | Items classified as "Speculative" do NOT include a magnitude line | π’ | |
| 16.25 | The magnitude line is preceded by a blank line | π’ | |
| 16.26 | Each item's evidence grade is appropriate, given the cited studies and data | π’ | |
| 16.27 | Each item is verifiable by the sources cited or by independent lookup | π’ | |
| 16.28 | Magnitude values are plausible and consistent with known clinical data | π’ | |
| 16.29 | No items are overstated relative to their evidence level | π’ | |
| 16.30 | No items are understated relative to their evidence level | π’ | |
| 16.31 | Each item (except Speculative) cites at least one PubMed link in the item | π’ | |
| 16.32 | The evidence level reflects the class of evidence behind the item. High: a human clinical endpoint (symptoms, events, function) or a clinical surrogate validated against outcomes in people (e.g., blood pressure, LDL, HbA1c, bone mineral density, eGFR, a named validated scale), shown in more than one trial. Medium: the same class of outcome in a single trial or in consistent observational data. Low: human data that are uncontrolled, indirect, or conflicting. Speculative: no human outcome data β in-vitro assays, animal work, and unvalidated biomarkers (e.g., MIC or zone assays, MDA, SOD, total antioxidant capacity) cap here regardless of how consistent they are. | π’ | |
| 16.33 | All four evidence-level headings (High, Medium, Low, Speculative) are present, in that order. A level with no items still carries the heading. An empty High or Medium is followed by one sentence naming the class of evidence that falls short; an empty Low or Speculative carries the heading alone. That sentence is not an H4 item and has no Magnitude line. | π’ | |
## 17. Benefit-Modifying Factors
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 17.1 | Genetic polymorphisms that may modify benefits are discussed where relevant (e.g., variants affecting drug transport, metabolism, or disease susceptibility) | π’ | |
| 17.2 | Baseline biomarker levels are discussed as a factor influencing benefits | π’ | |
| 17.3 | Known sex-based differences in benefits are discussed | π’ | |
| 17.4 | Pre-existing health conditions that may influence benefits are discussed | π’ | |
| 17.5 | Age-related considerations are discussed (including for those at the older end of the target range) | π’ | |
| 17.6 | Each factor is presented as a bulleted item with a short bold label followed by a descriptive explanation | π’ | |
| 17.7 | If none of the above is relevant to the intervention, it is briefly stated | N/A | Genetic, biomarker, sex, condition and age modifiers are all relevant and discussed. |
| 17.8 | Each factor is at most 45 words | π’ | |
## 18. Potential Risks & Side Effects
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 18.1 | All major known risks and side effects of the intervention are addressed (no significant omissions) | π’ | |
| 18.2 | Each item is a distinct outcome. The same outcome is not restated at a different granularity, split by population or endpoint, or repeated under another evidence level; where two items share a mechanism and an endpoint, they are merged. | π’ | |
| 18.3 | Content is framed for the target audience (see 1.12), not as population-level outcomes. | π’ | |
| 18.4 | A dedicated search for the intervention's complete side effect profile was performed using a drug reference source (e.g., prescribing information, drugs.com, Mayo Clinic) before writing this section. A statement by the author about the search is placed inside an HTML comment at the start of the section. | π’ | Search statement at line 238; cross-checked against the Rapamune label and mTOR-inhibitor adverse-event meta-analyses. |
| 18.5 | Each item is assigned a "Level of Evidence" grade | π’ | |
| 18.6 | Only the following four levels are used exactly: High, Medium, Low, Speculative | π’ | |
| 18.7 | No hybrid or intermediate levels are used (e.g., no "Low-Medium" or "Medium-High") | π’ | |
| 18.8 | Items are grouped by evidence level | π’ | |
| 18.9 | The groups are presented in the order: High, Medium, Low, Speculative | π’ | |
| 18.10 | The group High is presented as "### High π₯ π₯ π₯" | π’ | |
| 18.11 | The group Medium is presented as "### Medium π₯ π₯" | π’ | |
| 18.12 | The group Low is presented as "### Low π₯" | π’ | |
| 18.13 | The group Speculative is presented as "### Speculative π¨" | π’ | |
| 18.14 | The actual item titles are presented in H4 | π’ | |
| 18.15 | The actual item levels are not shown on a per-item basis | π’ | |
| 18.16 | Each item includes an annotation paragraph between the H4 title and the Magnitude line | π’ | |
| 18.17 | The annotation is 2β5 sentences and at most 90 words for High and Medium, 50 for Low, 35 for Speculative, covering: what the risk is, the proposed mechanism (if known), the evidence basis (e.g., "clinical trials", "FDA information", "post-marketing reports"), and any contextual nuance (severity, reversibility, at-risk populations, comparison to other agents in the class) | π’ | |
| 18.18 | The annotation is preceded and followed by a blank line | π’ | |
| 18.19 | Speculative items also include an annotation; if no controlled data exist, it notes the basis is mechanistic or from isolated reports | π’ | |
| 18.20 | Where evidence is directly conflicted, a "β οΈ Conflicted" flag appears directly after the item name in the title (not in the annotation) | π’ | |
| 18.21 | Conflicted evidence is explained in the annotation text. The annotation's last sentence states the net reading of the conflict in one sentence. | π’ | |
| 18.22 | Each item (except Speculative) includes a "**Magnitude:** " line giving the first of the following that the literature supports: a. an actual outcome as a figure β effect size, absolute or relative risk, prevalence, score change, or change per unit of exposure; b. the direction plus the conditions under which it holds (e.g., "prevalence rises steeply above 2 mg/L"), together with a statement that the literature report no outcome figure. | π’ | |
| 18.23 | If the literature supports neither, the line begins exactly "**Magnitude:** Not quantified in available studies." and continues with one sentence stating why the literature gives none (e.g., no controlled trial has measured this outcome; only case reports exist) | N/A | Every non-Speculative item satisfies 18.22a or 18.22b, so the fallback line is not needed. |
| 18.24 | Items classified as "Speculative" do NOT include a magnitude line | π’ | |
| 18.25 | The magnitude line is preceded by a blank line | π’ | |
| 18.26 | Each item's evidence grade is appropriate given the cited studies and data | π’ | |
| 18.27 | Each item is verifiable by the sources cited or by independent lookup | π’ | |
| 18.28 | Magnitude values are plausible and consistent with known clinical data | π’ | |
| 18.29 | No items are overstated relative to their evidence level | π’ | |
| 18.30 | No items are understated relative to their evidence level | π’ | |
| 18.31 | Each item (except Speculative) cites at least one PubMed link in the item | π’ | |
| 18.32 | The evidence level reflects the class of evidence behind the item. High: a human clinical endpoint (symptoms, events, function, documented adverse events) or a clinical surrogate validated against outcomes in people (e.g., blood pressure, LDL, HbA1c, bone mineral density, eGFR, a named validated scale), shown in more than one trial. Medium: the same class of outcome in a single trial or in consistent observational data. Low: human data that are uncontrolled, indirect, or conflicting. Speculative: no human outcome data β in-vitro cytotoxicity, animal work, and unvalidated biomarkers cap here regardless of how consistent they are. | π’ | |
| 18.33 | All four evidence-level headings (High, Medium, Low, Speculative) are present, in that order. A level with no items still carries the heading. An empty High or Medium is followed by one sentence naming the class of evidence that falls short; an empty Low or Speculative carries the heading alone. That sentence is not an H4 item and has no Magnitude line. | π’ | |
## 19. Risk-Modifying Factors
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 19.1 | Genetic polymorphisms that may modify risk or side effects are discussed where relevant (e.g., variants affecting drug transport, metabolism, or disease susceptibility) | π’ | |
| 19.2 | Baseline biomarker levels are discussed as a factor | π’ | |
| 19.3 | Known sex-based differences in risks and side effects are discussed | π’ | |
| 19.4 | Pre-existing health conditions that may influence risks and side effects are discussed | π’ | |
| 19.5 | Age-related considerations are discussed (including for those at the older end of the target range) | π’ | |
| 19.6 | Each factor is presented as a bulleted item with a short bold label followed by a descriptive explanation | π’ | |
| 19.7 | If none of the above is relevant to the intervention, it is briefly stated | N/A | Genetic, biomarker, sex, condition and age modifiers are all relevant and discussed. |
| 19.8 | Each factor is at most 40 words | π’ | |
## 20. Key Interactions & Contraindications
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 20.1 | Common prescription drug interactions are listed | π’ | |
| 20.2 | Over-the-counter medication interactions are listed | π’ | |
| 20.3 | Supplement interactions are listed | π’ | |
| 20.4 | Supplements known to have additive effects with the intervention are included (e.g., supplements that also lower blood pressure when evaluating an antihypertensive) | π’ | |
| 20.5 | Other intervention interactions are discussed where applicable | π’ | |
| 20.6 | Populations who should avoid this intervention are listed under the exact bolded label "**Populations who should avoid [intervention]:**", followed by a bulleted list. If there are none, the same label is present with the single item "None identified". The label is never omitted, renamed, or merged into another list. | π’ | |
| 20.7 | For drug or supplement interventions: when listing a drug class, include representative named drugs in parentheses (e.g., "CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit juice)") | π’ | |
| 20.8 | Each interaction states a severity (e.g., absolute contraindication, caution, monitor) and the clinical consequence (e.g., severe hypotension, increased bleeding risk) | π’ | |
| 20.9 | If a mitigating action is known (dose reduction, timing separation, monitoring schedule), it is stated | π’ | |
| 20.10 | Populations to avoid include specific thresholds or classifications where applicable (e.g., "recent MI (<90 days)", "Child-Pugh Class C", "NYHA Class IV") β not only general categories | π’ | |
| 20.11 | Each interaction is at most 45 words | π’ | |
## 21. Risk Mitigation Strategies
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 21.1 | Practical risk mitigation strategies are provided | π’ | |
| 21.2 | The strategies are specific to the risks identified in the Risks section | π’ | |
| 21.3 | The strategies are actionable by the target audience (see 1.12) | π’ | |
| 21.4 | Each strategy is presented as a bulleted item beginning with a short bold label, followed by descriptive explanation (e.g., "**Low starting dose with slow titration:** protocols typically begin at 2.5 mg daily, increasing to 5 mg after 1β2 weeks if tolerated") | π’ | |
| 21.5 | Strategies include specific parameters where applicable: doses, frequencies, thresholds, timeframes, or quantitative targets (e.g., "dose escalation of 250β500 mg every 1β2 weeks", "annual eGFR monitoring") | π’ | |
| 21.6 | Each strategy explicitly states the risk or consequence it mitigates (by naming the risk or describing what the strategy prevents) | π’ | |
| 21.7 | Each strategy is at most 40 words | π’ | |
## 22. Therapeutic Protocol
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 22.1 | A standard protocol is described as used by leading practitioners | π’ | |
| 22.2 | Where competing therapeutic approaches exist (e.g., conventional vs. integrative), the main alternatives are presented without framing one as the default | π’ | |
| 22.3 | Where possible, the expert or clinic that popularized each approach is cited | π’ | |
| 22.4 | Best time of day for the intervention is discussed | π’ | |
| 22.5 | For supplements/medications: the expected half-life of the compound in the human body is discussed | π’ | |
| 22.6 | For supplements/medications: whether to take as a single dose or split doses is discussed | π’ | |
| 22.7 | Genetic polymorphisms that may influence protocol or dose choice are discussed (e.g., APOE4, MTHFR, COMT, pharmacogenetically relevant variants) | π’ | |
| 22.8 | Known sex-based differences in response, dosing, or efficacy are discussed | π’ | |
| 22.9 | Age-related considerations are discussed (including for those at the older end of the target range) | π’ | |
| 22.10 | Baseline biomarker levels are discussed as a factor influencing response | π’ | |
| 22.11 | Pre-existing health conditions that may influence response are discussed | π’ | |
| 22.12 | Each protocol item is presented as a bulleted item with a short bold label followed by descriptive explanation | π’ | |
| 22.13 | Each item is at most 40 words | π’ | |
## 23. Discontinuation & Cycling
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 23.1 | Whether the intervention is meant to be lifelong or short-term is addressed | π’ | |
| 23.2 | Known withdrawal effects (if any) are discussed | π’ | |
| 23.3 | Tapering-off protocol is discussed (if applicable) | π’ | |
| 23.4 | Whether cycling is recommended for maintaining efficacy is addressed | π’ | |
| 23.5 | Each discontinuation or cycling consideration is presented as a bulleted item with a short bold label followed by descriptive explanation | π’ | |
| 23.6 | Each item is at most 40 words | π’ | |
## 24. Sourcing and Quality
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 24.1 | Source, purity, and formulation considerations are addressed | π’ | |
| 24.2 | What to look for is explained (e.g., third-party testing, specific nutrient forms) | π’ | |
| 24.3 | Reputable brands or compounding pharmacies are mentioned where relevant | π’ | |
| 24.4 | If the section is not applicable to the intervention, this is briefly noted | N/A | The section applies; sourcing, purity and formulation are addressed. |
| 24.5 | Each sourcing consideration is presented as a bulleted item with a short bold label followed by descriptive explanation | π’ | |
| 24.6 | Each item is at most 45 words | π’ | |
## 25. Practical Considerations
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 25.1 | Time to effect is discussed: how long does it typically take to observe benefits? | π’ | |
| 25.2 | Common pitfalls are discussed: what mistakes do people commonly make? | π’ | |
| 25.3 | Regulatory status is addressed if applicable (e.g., off-label use, FDA regulation) | π’ | |
| 25.4 | Cost and accessibility are briefly noted if the intervention is exceptionally expensive or difficult to access | π’ | |
| 25.5 | Each consideration is presented as a bulleted item with a short bold label followed by descriptive explanation (e.g., "**Time to effect:**") | π’ | |
| 25.6 | Each item is at most 45 words | π’ | |
## 26. Interaction with Foundational Habits
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 26.1 | Interaction with sleep is analyzed (e.g., Can it disrupt sleep? Improve sleep quality?) | π’ | |
| 26.2 | Interaction with nutrition is analyzed (e.g., Best with a specific diet? Depletes nutrients?) | π’ | |
| 26.3 | Interaction with exercise is analyzed (e.g., Blunts hypertrophy? Timing around workouts?) | π’ | |
| 26.4 | Interaction with stress management is analyzed (e.g., Affects cortisol or stress response?) | π’ | |
| 26.5 | Each interaction is presented as a bulleted item with a bold label (Sleep, Nutrition, Exercise, Stress management) followed by a descriptive explanation | π’ | |
| 26.6 | Each interaction states the direction of the interaction (direct, indirect, none, potentiating, blunting), the proposed mechanism where known, and specific practical considerations where applicable (e.g., foods to include or avoid, timing relative to dosing, technique variants, named studies) | π’ | |
| 26.7 | Each item is at most 55 words | π’ | |
## 27. Monitoring Protocol & Defining Success
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 27.1 | Baseline labs and tests are specified (what to do before starting) | π’ | |
| 27.2 | Ongoing labs and tests are specified with monitoring frequency | π’ | |
| 27.3 | Lab tests are presented in a table with the following columns: Biomarker, Optimal Functional Range, Why Measure It?, Context/Notes | π’ | |
| 27.4 | Optimal ranges reflect functional medicine practitioner guidance (not just conventional reference ranges) | π’ | |
| 27.5 | Where the conventional reference range differs meaningfully from the optimal functional range, it is included in the Context/Notes column | π’ | |
| 27.6 | Each Optimal Functional Range cell states a value or range. Where no established target exists, the cell says so and gives what to track instead (e.g., change from the individual's own baseline). | π’ | |
| 27.7 | The "Why Measure It?" column provides extremely concise explanations | π’ | |
| 27.8 | The Context/Notes column covers relevant details such as fasting requirements, best paired tests, and time-of-day considerations | π’ | |
| 27.9 | Qualitative markers are discussed (e.g., sleep quality, energy levels, cognitive clarity) | π’ | |
| 27.10 | Baseline testing is introduced with a descriptive statement outside the biomarker table (not only implied by the table's contents) | π’ | |
| 27.11 | Ongoing monitoring is introduced with a cadence statement specifying timepoints (e.g., "at 1 week, 4 weeks, then every 3β6 months" or "every 6β12 months") | π’ | |
| 27.12 | Qualitative markers are presented as a bulleted list | π’ | |
| 27.13 | If the section is not applicable to the intervention, this is briefly noted | N/A | The section applies; baseline and ongoing monitoring are specified. |
| 27.14 | The baseline and ongoing narrative outside the biomarker table is 100β150 words | π’ | 131 words. |
## 28. Emerging Research
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 28.1 | Content is framed for the target audience (see 1.12), not as population-level outcomes. | π’ | |
| 28.2 | Major ongoing clinical trials are mentioned (e.g., from clinicaltrials.gov) | π’ | |
| 28.3 | All clinical trial NCT IDs are hyperlinked to "https://clinicaltrials.gov/study/\" | π’ | |
| 28.4 | Areas of future research that could change current understanding are noted | π’ | |
| 28.5 | Emerging research is presented from all relevant directions β studies that could strengthen and studies that could weaken the case for the intervention are both included | π’ | |
| 28.6 | All cited publications include a hyperlink (PubMed, DOI, or publisher URL) | π’ | |
| 28.7 | Every NCT ID, PMID, and DOI mentioned in the section is an active hyperlink, not plain text | π’ | |
| 28.8 | Any other referenced source with a known URL is linked | π’ | |
| 28.9 | Ongoing trials are presented with a descriptive title or aim, the NCT ID as a hyperlink (or a note if no NCT ID exists), and key details such as participant count, phase, or primary endpoint where available | π’ | |
| 28.10 | Future research areas reference specific studies or meta-analyses by author/year with a hyperlink where relevant published evidence exists | π’ | |
| 28.11 | Emerging Research entries are presented as bulleted items beginning with a short bold label | π’ | |
| 28.12 | Each link is verified per Section 5 (Loading, Content, Semantics) | π’ | |
| 28.13 | For PubMed links: the PubMed-retrieved title matches the title in the ER | π’ | |
| 28.14 | For clinicaltrials.gov links: the NCT ID resolves to a trial related to the intervention | π’ | All five NCT IDs resolve to rapamycin/everolimus aging trials. |
| 28.15 | Each item is at most 55 words | π’ | |
## 29. Conclusion
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 29.1 | The conclusion is a cohesive summary of the document as a whole | π’ | |
| 29.2 | It is framed for the target audience (see 1.12) | π’ | |
| 29.3 | It reflects what the intervention is, the main benefits, the main risks and considerations | π’ | |
| 29.4 | It reflects on the overall quality of the evidence base (including any conflicts of interest per 2.8β2.10) | π’ | |
| 29.5 | It is 150β250 words | π’ | 230 words. |
| 29.6 | It is consistent with the evidence levels assigned in the Benefits and Risks sections | π’ | |
| 29.7 | Where evidence is uncertain, the conclusion conveys that uncertainty | π’ | |
| 29.8 | It DOES NOT introduce new evidence or claims not previously discussed | π’ | |
| 29.9 | It DOES NOT use acronyms that would require glossary expansion or technical classifications that require specialist knowledge, uses plain-language terms instead | π’ | |
| 29.10 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | π’ | |
| 29.11 | It DOES NOT cite effect sizes, relative risks, or statistical results | π’ | |
| 29.12 | It DOES NOT use prescriptive or advisory language β it summarizes evidence, not what anyone should do | π’ | |
| 29.13 | It DOES NOT address the reader directly | π’ | |
| 29.14 | It DOES NOT force a pro-vs-con structure or equal treatment of competing positions | π’ | |
| 29.15 | It DOES NOT state what further evidence is needed or what should be done | π’ | |
| 29.16 | It DOES NOT frame its takeaway around an average-risk or general population | π’ | |
| 29.17 | It DOES NOT close on generic cautions that apply to a population the reader is not part of | π’ | |
| 29.18 | It DOES NOT characterize any position on the intervention as the accepted, mainstream, or settled view | π’ | |
| 29.19 | It DOES NOT frame one position as the default and the other as requiring extra justification | π’ | |
| 29.20 | The conclusion section ends with a line stating "**\[Top]\(#top) - \[Benefits]\(#expected-benefits) - \[Risks]\(#potential-risks--side-effects) - \[Protocol]\(#therapeutic-protocol)**" | π’ | |
| 29.21 | The ending line is preceded by a blank line | π’ | |
## 30. Motivation
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 30.1 | The motivation section is located after the title and frontmatter but before all other sections | π’ | |
| 30.2 | A statement by the author that the section was only written after the rest of the document was written to have the full scope of the topic is placed inside an HTML comment | π’ | |
| 30.3 | The section provides a brief overview of the topic | π’ | |
| 30.4 | The section covers the essential aspects of the topic | π’ | |
| 30.5 | The section is a concise, accessible introduction | π’ | |
| 30.6 | The purpose and focus of the document are clearly explained | π’ | |
| 30.7 | The motivation does NOT jump to conclusions or preempt the analysis results | π’ | |
| 30.8 | The motivation does NOT characterize any position on the intervention as the accepted, mainstream, or settled view β it presents the debate neutrally | π’ | |
| 30.9 | Where relevant, the motivation connects the intervention to the health and longevity lens of the target audience (see 1.12) | π’ | |
| 30.10 | The motivation consists of three paragraphs | π’ | |
| 30.11 | First paragraph explains in plain language what the intervention is and why it is of interest | π’ | |
| 30.12 | Second paragraph gives additional context β e.g., historical use, prevalence, or a single headline finding that motivates the review | π’ | |
| 30.13 | The final paragraph is a crisp statement of what this review examines and why | π’ | |
| 30.14 | The final paragraph does not use evaluative or advisory language β it states what the review examines, not what anyone should do | π’ | |
| 30.15 | The motivation is 150β200 words | π’ | 183 words. |
| 30.16 | DOES NOT use acronyms that would require glossary expansion or technical classifications that require specialist knowledge, uses plain-language terms instead | π’ | |
| 30.17 | DOES NOT parenthetically define standard terms (e.g., "CRP (C-reactive protein, a general marker of systemic inflammation)") | π’ | |
| 30.18 | Parenthetical alternate names are acceptable when introducing the intervention. E.g., "Niacin (vitamin B3)" | π’ | |
| 30.19 | DOES NOT cite specific trials (names, years, sample sizes, p-values) | π’ | |
| 30.20 | DOES NOT cite effect sizes, relative risks, or statistical results | π’ | |
| 30.21 | DOES NOT contain exhaustive mechanism-of-action descriptions; a single sentence on the primary mechanism is sufficient | π’ | |
| 30.22 | DOES NOT list every health domain the intervention touches, mentions the most notable 2β3 at most | π’ | |
| 30.23 | DOES NOT mention specific influencers, podcasters, or biohackers (e.g., "Peter Attia recommendsβ¦") | π’ | |
| 30.24 | The motivation section ends with a line stating "**\[Benefits]\(#expected-benefits) - \[Risks]\(#potential-risks--side-effects) - \[Protocol]\(#therapeutic-protocol) - \[Conclusion]\(#conclusion)**" | π’ | |
| 30.25 | The ending line is preceded by a blank line | π’ | |
## 31. End of Document
| # | Description | Result | Comments |
|---|-------------|:------:|----------|
| 31.1 | The document does not include content past the conclusion | π’ | |
## Issues 28/08/2026 16:20
Pass rate 100.00%. No issues found.
## Issues 28/08/2026 16:07
1. **1.6 / 1.7 / 1.8 β imperative labels in Risk Mitigation:** The bold labels in Risk Mitigation Strategies (lines 393, 395, 397, 399, 401, 403, 405) are bare imperatives β "Start low and titrate", "Take a dose holiday at the first mouth ulcer", "Avoid grapefruit and audit all co-medications and supplements" β which address the reader directly and read as clinical instruction rather than presented evidence.
2. **18.27 / 18.28 β proteinuria magnitude does not match source:** Line 278 credits PMID 25146383 with "pooled data from 10 randomized trials in 2,027 kidney-transplant recipients" and a standardized mean difference of 0.23 (95% CI 0.15 to 0.32); that meta-analysis reports nine trials totalling 2,323 patients and publishes no pooled effect estimate for proteinuria.
## Fixes 28/08/2026 16:07
1. **1.6 / 1.7 / 1.8 β imperative labels rewritten as noun phrases:** The seven directive bold labels in Risk Mitigation Strategies were converted to descriptive noun phrases β "Start low and titrate" to "Low starting dose with slow titration", "Measure a whole-blood trough before escalating" to "Whole-blood trough level before each escalation", "Pause for infection, surgery and dental work" to "Drug pause around infection, surgery and dental work", "Track lipids and fasting insulin quarterly at first" to "Initially quarterly lipid and fasting insulin tracking", "Take a dose holiday at the first mouth ulcer" to "Dose holiday at the first mouth ulcer", "Avoid grapefruit and audit all co-medications and supplements" to "Grapefruit exclusion and a full co-medication and supplement audit", and "Maintain vaccination status before starting" to "Vaccination status brought up to date before starting", so the section presents evidence rather than addressing the reader.
2. **1.6 / 1.7 / 1.8 β titration strategy trimmed to the word limit:** The relabelled titration strategy exceeded the 40-word cap, so "guided by a trough level (measured just before the next dose)" was shortened to "guided by a pre-dose trough level", bringing the item back to 36 words.
3. **18.27 / 18.28 β proteinuria magnitude corrected to the source:** The magnitude line for Protein Leakage Into the Urine claimed "10 randomized trials in 2,027 kidney-transplant recipients" and a standardized mean difference of 0.23 (95% CI 0.15 to 0.32); it now states the meta-analysis pooled nine randomized trials in 2,323 recipients, reports the direction of the proteinuria increase only, and publishes no pooled effect estimate. The link itself was unchanged.
## Issues 28/08/2026 15:06
1. **18.1 β Gastrointestinal effects omitted:** The Potential Risks & Side Effects section (lines 236β322) has no item for diarrhea, nausea, abdominal pain, constipation or dyspepsia, which the sirolimus prescribing information lists as very common (25β38%) and which a meta-analysis of 18 randomized trials puts at a relative risk of 1.94 (95% CI 1.60β2.36) for all-grade diarrhea on mTOR inhibitors.
## Fixes 28/08/2026 15:06
1. **18.1 β gastrointestinal effects were missing:**
| LINK ADDED: [https://pubmed.ncbi.nlm.nih.gov/25994247/](https://pubmed.ncbi.nlm.nih.gov/25994247/) | tried: β | outcome: New "Gastrointestinal Upset" item added at the end of the High group in Potential Risks & Side Effects; the Magnitude line needed a pooled source for the diarrhea risk, and Abdel-Rahman & Fouad's meta-analysis of 18 randomized mTOR-inhibitor trials supplies it. |
The item covers diarrhea, nausea, abdominal pain, constipation and indigestion, with the mucosal mechanism, the evidence basis, and the note that these were also recorded at 1 mg daily in healthy older adults. It was placed after "Protein Leakage Into the Urine" so that the first-use explanation of "relative risk" stays at the Raised Blood Lipids item.
## Issues 28/08/2026 15:03
1. **1.9 β Unexplained specialist jargon:** "It measured antibody titers, not infections" (line 164) uses "titers" where "levels" is equally precise, and "shorter escape latency" (line 206) is a maze-test term left unexplained.
2. **4.6 β Cytomegalovirus not explained:** "cytomegalovirus infection was roughly halved" (line 300) introduces an uncommon condition name with no plain-language explanation at first use.
## Fixes 28/08/2026 15:03
1. **1.9 β Replaced jargon with plain wording:** Changed "It measured antibody titers, not infections" to "It measured antibody levels, not infections" (Enhanced Response to Vaccination annotation), and "found shorter escape latency" to "found faster maze-escape times" (Cognitive Protection annotation).
2. **4.6 β Cytomegalovirus explained at first use:** Added the parenthetical "(a common latent virus that flares when immune defences are damped)" after "cytomegalovirus infection" in the Increased Susceptibility to Infection magnitude line.
## Issues 28/08/2026 14:41
1. **4.9 β Explanations not in parentheses:** Several plain-language explanations are appositives set off by commas rather than parentheses, e.g. "angioedema, sudden deep swelling of the lips, tongue or airway" (line 356), "FKBP12, a small intracellular protein that acts as its docking partner" (line 128), and "the podocytes, the filtering cells of the kidney" (line 270).
2. **24.3 β No brand or pharmacy named:** The Sourcing and Quality bullet at line 448 is titled "Reputable compounding pharmacies" but names no brand and no pharmacy, citing only an accreditation body.
## Fixes 28/08/2026 14:41
1. **4.9 β Explanations moved into parentheses:** Converted the comma appositive glosses at lines 128, 184, 192, 270 and 356 into parenthetical form, e.g. "FKBP12, a small intracellular protein..." became "FKBP12 (a small intracellular protein...)" and "angioedema, sudden deep swelling of the lips, tongue or airway," became "angioedema (sudden deep swelling of the lips, tongue or airway),".
2. **24.3 β Named commercial brands:** Added "Reputable tablets include Rapamune (Pfizer) and generics from Zydus, Dr. Reddy's and Greenstone." to the "Commercial versus compounded" bullet in Sourcing and Quality, and trimmed "compared with the commercial tablet" to "of the commercial tablet" so the item stays within the 45-word limit.
## Issues 28/08/2026 14:25
1. **9.5 β FoundMyFitness content overlooked:** Line 65 states that FoundMyFitness covers rapamycin "only in members-only Q&A episodes, whose content is not publicly readable", but the site carries a substantive, publicly readable topic article on rapamycin (foundmyfitness.com/topics/rapamycin, updated 27 Jul 2026), so relevant content from a priority expert was omitted on an incorrect basis.
2. **16.1 β Ovarian aging benefit omitted:** Expected Benefits does not address delayed ovarian aging, although it is one of the most prominent rapamycin longevity claims, rests on mouse data of the same class as the Speculative items at lines 196 and 204, and its first human trial is featured by the ER itself at line 505.
3. **18.26 / 18.30 / 18.32 β Proteinuria graded too low:** "Protein Leakage Into the Urine" (line 274) sits under Medium and its annotation describes the evidence as "consistent observational and conversion-cohort data", but the source cited at line 278 is a meta-analysis of nine randomized conversion trials in 2,323 patients β a validated kidney surrogate shown in more than one trial, which is the High class.
4. **28.9 β Trial drug misidentified:** Line 513 describes NCT07191353 as testing whether "the drug" adds to or subtracts from the bone response to training, but the registry record shows the trial administers everolimus, a rapamycin analogue, not rapamycin.
## Fixes 28/08/2026 14:25
1. **9.5 β FoundMyFitness item added:**
| LINK ADDED: [https://www.foundmyfitness.com/topics/rapamycin](https://www.foundmyfitness.com/topics/rapamycin) | tried: β | outcome: Publicly readable, substantive FoundMyFitness article on rapamycin (discovery, mechanism, longevity evidence, adverse effects), retrieved with d-browser and d-fetch; added as the fifth Recommended Reading item, attributed to the publication because the page carries no byline. |
2. **9.5 β closing note corrected:** Rewrote the note at the end of Recommended Reading, dropping the false claim that FoundMyFitness covers rapamycin only in members-only, non-public Q&A episodes; it now records two unrepresented priority platforms (Huberman Lab, Chris Kresser) instead of three.
3. **16.1 β Delayed ovarian aging benefit added:**
| LINK ADDED: [https://pubmed.ncbi.nlm.nih.gov/28544226/](https://pubmed.ncbi.nlm.nih.gov/28544226/) | tried: β | outcome: Dou et al., Aging Cell 2017, "Short-term rapamycin treatment increases ovarian lifespan in young and middle-aged female mice", confirmed with d-pubmed; cites the new Speculative benefit item "Delayed Ovarian Aging". |
The new H4 item sits at the end of the Speculative group and carries no Magnitude line, matching the other animal-only entries.
4. **18.26 / 18.30 / 18.32 β Proteinuria regraded to High:** Moved "Protein Leakage Into the Urine" from the Medium group to High and replaced "Evidence is consistent observational and conversion-cohort data" with "Evidence is pooled randomized conversion trials, supported by observational cohorts", matching the meta-analysis of nine randomized conversion trials it cites.
5. **28.9 β Trial drug named:** In the NCT07191353 entry, changed "testing whether the drug adds to or subtracts from the bone response to training" to "testing whether the rapamycin analogue everolimus adds to or subtracts from the bone response to training", matching the registry record.
## Issues 28/08/2026 14:18
1. **4.6 β Folliculitis not explained at first use:** "scalp folliculitis" first appears at line 308 in "Acne-Like Eruptions and Other Skin Complaints" and again at line 310 with no plain-language explanation, while every comparable term in the review (stomatitis, dehiscence, lymphocele, lymphedema, pneumonitis, proteinuria, dysbiosis, angioedema) is glossed at first use.
2. **18.26 / 18.29 / 18.32 β Gut microbiome risk graded above its evidence class:** "Gut Barrier and Microbiome Disruption" (line 294) is placed under Low, but its only evidence is an exploratory PEARL subgroup measuring a proprietary gut-dysbiosis index and an intestinal-permeability trend β unvalidated biomarkers that the annotation itself describes as having "no clinical correlate", which rule 18.32 caps at Speculative.
## Fixes 28/08/2026 14:18
1. **4.6 β Folliculitis now glossed at first use:** Added the parenthetical "(inflamed hair follicles)" to "scalp folliculitis" at its first occurrence in "Acne-Like Eruptions and Other Skin Complaints"; the annotation stays within the 50-word Low limit at 49 words.
2. **18.26 / 18.29 / 18.32 β Gut microbiome item regraded to Speculative:** Moved "Gut Barrier and Microbiome Disruption" from the Low group to the Speculative group, since its endpoints are unvalidated exploratory biomarkers with no clinical correlate.
3. **18.24 β Magnitude line removed from the regraded item:** Deleted the "**Magnitude:**" line from "Gut Barrier and Microbiome Disruption", because Speculative items carry no magnitude line.
4. **18.17 β Gut microbiome annotation shortened to the Speculative limit:** Rewrote the annotation from 48 words to 35 words to meet the 35-word Speculative cap, keeping the dysbiosis gloss, the male 10 mg finding, the female permeability trend and the absence of a clinical correlate, and folding the PubMed citation for the 48-week trial into the annotation text (the URL itself is unchanged).
## Issues 28/08/2026 14:00
1. **5.11 / 9.22 β FoundMyFitness episode is paywalled:** The Rhonda Patrick link at line 53 loads the genuine page, but the episode body is members-only, so no content matching the annotation at line 55 is retrievable; the item therefore fails the Section 5 verification required by 9.22.
2. **18.1 β dermatologic adverse effects omitted:** Acne-like eruptions, scalp folliculitis and nail changes β reported in 46%, 26% and 74% of an 80-patient prospective sirolimus cohort and a frequent reason for discontinuation β are absent from the Risks section (lines 232-314).
3. **18.22 β swelling magnitude omits an available figure:** The Magnitude line at line 276 states that no incidence is reported for extremity swelling, but the literature supports option (a): chronic edema was present in 55% of an 80-patient prospective sirolimus cohort.
4. **1.7 / 1.8 β advisory imperatives address the reader:** Lines 392, 440 and 444 give instructions rather than presenting information ("use a pharmacy accredited by...", "request a certificate of analysis", "Keep tablets in the original blister"), as do the monitoring-table cells at lines 479, 480, 482 and 489 ("Watch the trend, not just the reference flag", "Draw testosterone before 10 a.m.").
## Fixes 28/08/2026 14:00
1. **5.11 / 9.22 β paywalled Rhonda Patrick item dropped:**
| LINK REMOVED: [https://www.foundmyfitness.com/episodes/qa-40-dr-rhonda-patrick](https://www.foundmyfitness.com/episodes/qa-40-dr-rhonda-patrick) | tried: d-browser, d-fetch | outcome: the genuine page loads but the episode body is members-only, and a FoundMyFitness site search returned no openly readable rapamycin episode, so no URL retrieves the cited source |
The list item and its annotation were deleted from Recommended Reading, which now carries four items.
2. **9.13 / 9.26 / 9.27 β unrepresented-platform note rewritten:** The closing note now states that four items are listed rather than five and names FoundMyFitness as unrepresented because its rapamycin coverage is members-only; the section's opening sentence was changed from "skeptical" to "cautious" to match the remaining items.
3. **18.1 β new skin-effects item, prospective cohort source:**
| LINK ADDED: [https://pubmed.ncbi.nlm.nih.gov/15729175/](https://pubmed.ncbi.nlm.nih.gov/15729175/) | tried: β | outcome: MahΓ© et al. 2005 supplies the acne-like eruption (46%), scalp folliculitis (26%), nail change (74%) and discontinuation (7%) rates for the added item |
A Low item "Acne-Like Eruptions and Other Skin Complaints β οΈ Conflicted" was added with a 46-word annotation, a net-reading sentence and a Magnitude line.
4. **18.1 β new skin-effects item, case-control source:**
| LINK ADDED: [https://pubmed.ncbi.nlm.nih.gov/23991694/](https://pubmed.ncbi.nlm.nih.gov/23991694/) | tried: β | outcome: Γzcan et al. 2013 supplies the contradicting finding (acne no more frequent than in 50 recipients not on sirolimus) that justifies the β οΈ Conflicted flag |
5. **18.22 β swelling magnitude now carries an outcome figure:**
| LINK ADDED: [https://pubmed.ncbi.nlm.nih.gov/15729175/](https://pubmed.ncbi.nlm.nih.gov/15729175/) | tried: β | outcome: the 55% chronic-edema prevalence supplies option (a) of 18.22, which the previous "no incidence reported" wording had skipped |
The Magnitude line for "Peripheral and Extremity Swelling" now opens with the 55% figure and keeps the existing review link as supporting context.
6. **1.7 / 1.8 β advisory imperatives rewritten as description:** "Start at 2 to 3 mg weekly" became "Protocols start at...", "use a pharmacy accredited by... and request a certificate of analysis" became "protocols specify a pharmacy accredited by... and a certificate of analysis", and "Keep tablets in the original blister" became "Tablets are kept in the original blister".
7. **1.8 β monitoring-table cells de-imperativized:** "Draw 24 hours after the dose" became "The draw is taken 24 hours after the dose", "Watch the trend, not just the reference flag" became "The trend matters more than the reference flag", "Pair with fasting glucose" became "Paired with fasting glucose", and "Draw testosterone before 10 a.m." became "Testosterone is drawn before 10 a.m."
## Issues 28/08/2026 13:32
1. **1.7 β Advisory imperatives to the reader:** Line 324 instructs "avoid entirely rather than time around it" and line 452 states "Grapefruit and Seville orange must be avoided entirely"; both are guidance rather than presented information.
2. **4.2 β "Rapalog" drug class not explained:** The bold label "**Rapalog pharmacology comparison:**" at line 497 introduces the drug-class term "rapalog" with no plain-language explanation at first use.
3. **16.1 β Musculoskeletal benefit omitted:** The ER's own Systematic Reviews entry (lines 121β123) reports reduced bone resorption in fourteen human studies and an ongoing bone trial is listed at line 501, yet Expected Benefits contains no bone or joint item.
4. **16.22 β Skin-aging magnitude gives only p-values:** The Magnitude line at line 186 reports p = 0.008 and p = 0.0077, which are not outcome figures, without the statement that the literature reports no outcome figure.
5. **18.1 β Peripheral edema omitted:** Peripheral edema, among the most frequent adverse reactions in the sirolimus prescribing information the author states was reviewed (line 222), is absent from Potential Risks & Side Effects.
6. **18.22 β Glucose magnitude carries no figure:** Line 278 gives only direction ("no association", "a slight HbA1c increase in men on 5 mg weekly") with neither an outcome figure nor a statement that the literature reports none.
7. **20.8 β "Other interventions" states no severity:** The interaction at line 342 gives the clinical consequence and a mitigating action but omits the severity grade that every other item in the section carries.
## Fixes 28/08/2026 13:32
1. **1.7 β advisory imperatives removed:** Rewrote line 324 from "avoid entirely rather than time around it" to "so protocols exclude these foods entirely rather than timing around them", and line 452 from "must be avoided entirely" to "are excluded entirely", so both state practice rather than instruct the reader.
2. **4.2 β rapalog drug class explained:** Changed the Emerging Research item at line 497 from "comparing rapamycin against analogues" to "comparing rapamycin against rapalogs (chemically modified versions of rapamycin)", giving the class name its plain-language explanation at first use.
3. **16.1 β bone benefit item added:** Added a "Reduced Bone Breakdown" item under Low in Expected Benefits, with annotation and Magnitude line, covering the human bone-resorption finding the ER already cited in Systematic Reviews.
| LINK ADDED: [https://pubmed.ncbi.nlm.nih.gov/35861940/](https://pubmed.ncbi.nlm.nih.gov/35861940/) | tried: β | outcome: Lin et al. 2022 systematic review is the source for the new benefit item; the same PMID was already cited in the Systematic Reviews section and resolves to the matching title on d-pubmed. |
4. **16.22 β skin-aging magnitude completed:** Reworked the Magnitude line at line 186 so the p-values sit alongside the direction of change and added "The trial reports significance testing only and gives no outcome figure for the size of either change."
5. **18.1 β peripheral swelling risk added:** Added a "Peripheral and Extremity Swelling" item under Medium in Potential Risks & Side Effects, with annotation and Magnitude line, covering the frequently reported extremity edema that was previously absent.
| LINK ADDED: [https://pubmed.ncbi.nlm.nih.gov/17038868/](https://pubmed.ncbi.nlm.nih.gov/17038868/) | tried: β | outcome: Buhaescu et al. 2006 review lists extremity oedema among the effects frequently associated with sirolimus; PMID resolves on d-pubmed with a matching title, and the link text names it as a review. |
6. **18.22 β glucose magnitude completed:** Sharpened line 278 to "confined to men and to the 5 mg weekly arm" and added "Neither source reports an outcome figure for glucose tolerance at longevity doses."
7. **20.8 β severity added to other interventions:** Relabelled the item as "**Other interventions (elective surgery, dental implants, cosmetic procedures):**" and opened it with "Temporary contraindication around the procedure", followed by the clinical consequence, matching the severity-plus-consequence pattern of the rest of the section.
## Issues 28/08/2026 13:18
1. **4.2 β Antimetabolite drug class unexplained:** "antimetabolite" is used as a drug class name at line 256 ("the comparator antimetabolite regimens") and again at line 284 without the plain-language explanation required at first use.
2. **28.9 β "First trial" claim contradicted:** Line 499 calls NCT06727305 "the first trial designed to distinguish between agents in this class", but NCT05949658 (line 497, started 2024-05-15) and NCT06658093 (line 495, RESTOR) both compare sirolimus against everolimus and began before NCT06727305 (started 2026-05-11).
## Fixes 28/08/2026 13:18
1. **4.2 β Antimetabolite drug class explained:** Added a plain-language gloss at first use in the Impaired Wound Healing magnitude line (line 256): "antimetabolite regimens" is now "antimetabolite regimens (a drug class that blocks cell division by mimicking the building blocks of DNA)".
2. **28.9 β Unsupported "first trial" claim removed:** Rewrote the NCT06727305 entry (line 499), replacing "comparing inhibitors on aging endpoints, the first trial designed to distinguish between agents in this class" with the trial's actual registered design β "comparing sirolimus against everolimus, with a blood panel of senescence markers as its aging endpoint" β and specified the 65-and-over age range.
## Issues 28/08/2026 13:15
1. **1.7 β Advisory "should" in monitoring table:** The reproductive-markers row at line 477 states "Women should log cycle length and regularity rather than rely on a single laboratory value", which advises rather than presents information.
2. **4.4 β p-value not explained at first use:** The statistical term "p" first appears at line 186 ("p = 0.008", "p = 0.0077") with no plain-language explanation, although hazard ratio, confidence interval and relative risk are all explained elsewhere.
3. **9.5 / 9.26 β Huberman rapamycin coverage mischaracterized:** The closing note at line 69 claims Andrew Huberman "addresses rapamycin only briefly inside broader longevity question-and-answer episodes", but hubermanlab.com carries the guest episode "Dr. Peter Attia: Supplements for Longevity & Their Efficacy" with two dedicated rapamycin chapters, so the stated reason for the omission is inaccurate.
## Fixes 28/08/2026 13:15
1. **1.7 β Advisory "should" in monitoring table:** Rewrote the reproductive-markers Context/Notes cell at line 477 from "Women should log cycle length and regularity rather than rely on a single laboratory value" to "In women, cycle length and regularity are logged over time rather than read from a single laboratory value", so the row presents practice instead of advising.
2. **4.4 β p-value not explained at first use:** Added a plain-language gloss for "p" at its first use in the Magnitude line at line 186 ("p is the probability that a result this large arose by chance, so smaller values mean a firmer finding").
3. **9.5 / 9.26 β Huberman rapamycin coverage mischaracterized:** Rewrote the closing note of Recommended Reading (line 69) to state that the Huberman Lab does cover rapamycin in depth but that its substantive treatment is a conversation with Peter Attia, who is already represented by his own dedicated episode, so a second entry would duplicate the same expert; the Chris Kresser explanation was kept and separated into its own sentence. No link was added, removed or replaced.
## Issues 28/08/2026 12:52
1. **1.8 β Expected Benefits addresses the reader:** Line 148 opens with "For readers weighing an off-label longevity protocol, the honest summary isβ¦", speaking to the reader instead of presenting the evidence.
2. **2.12 β Findings attributed to trials without links:** Lines 209, 315, 398, 458 and 490 attribute results to "the one long human trial", "the healthy-adult trial", "pooled mouse data" and "a randomized trial" with no hyperlink; the blood urea nitrogen, calcium and dysbiosis signals at line 315 appear nowhere else in the document.
3. **18.2 β Male reproductive outcome split by evidence level:** "Reproductive and Menstrual Effects" (Low, line 292) already reports reduced sperm counts, and "Male Reproductive Tissue Damage" (Speculative, line 300) restates the same outcome from rodent histology.
## Fixes 28/08/2026 12:52
1. **1.8 β Expected Benefits no longer addresses the reader:** Changed the framing sentence at line 148 from "For readers weighing an off-label longevity protocol" to "For a longevity-oriented adult weighing an off-label protocol", keeping the audience framing without speaking to the reader.
2. **2.12 β Sex modifier findings now linked:**
| LINK ADDED: [https://pubmed.ncbi.nlm.nih.gov/27519886/](https://pubmed.ncbi.nlm.nih.gov/27519886/), [https://pubmed.ncbi.nlm.nih.gov/40188830/](https://pubmed.ncbi.nlm.nih.gov/40188830/) | tried: β | outcome: the Benefit-Modifying "Sex" bullet attributed findings to the mouse meta-analysis and to the one long human trial without a hyperlink |
Link text wraps the existing wording ("pooled mouse data", "the one long human trial"), so the item's word count is unchanged.
3. **2.12 β Male-specific trial signals now linked:**
| LINK ADDED: [https://pubmed.ncbi.nlm.nih.gov/40188830/](https://pubmed.ncbi.nlm.nih.gov/40188830/) | tried: β | outcome: the Risk-Modifying "Sex" bullet cited blood urea nitrogen, calcium and dysbiosis signals from "the healthy-adult trial", a claim made nowhere else in the document, with no link |
4. **2.12 β Therapeutic Protocol sex bullet now linked:**
| LINK ADDED: [https://pubmed.ncbi.nlm.nih.gov/40188830/](https://pubmed.ncbi.nlm.nih.gov/40188830/) | tried: β | outcome: "Every measured benefit in the long human trial appeared in women" attributed a finding to a specific trial without a hyperlink |
5. **2.12 β Exercise interaction now linked:**
| LINK ADDED: [https://pubmed.ncbi.nlm.nih.gov/41985884/](https://pubmed.ncbi.nlm.nih.gov/41985884/) | tried: β | outcome: the Foundational Habits "Exercise" bullet attributed the attenuated functional gains to "a randomized trial" without a hyperlink |
6. **2.12 β Qualitative marker now linked:**
| LINK ADDED: [https://pubmed.ncbi.nlm.nih.gov/40188830/](https://pubmed.ncbi.nlm.nih.gov/40188830/) | tried: β | outcome: the joint-comfort marker referred to the improvement "in the one long trial" without a hyperlink |
7. **18.2 β Male reproductive outcome merged:** Removed the Speculative item "Male Reproductive Tissue Damage" and folded its rodent finding into the Low item "Reproductive and Menstrual Effects" ("; rodent studies add testicular degeneration"), so the outcome is no longer split across two evidence levels. The Low annotation stays within the 50-word limit at 49 words, and the Speculative heading retains an item.
## Issues 28/08/2026 12:47
1. **18.28 β Microbiome subgroup counts reversed:** Line 284 states the PEARL microbiome subgroup was "50 women and 31 men"; the paper reports 31 female and 50 male.
2. **18.27 β Microbiome subgroup mischaracterized:** Line 282 calls it "A pre-planned subgroup"; the PEARL paper describes the samples as a subset submitted for exploratory analysis, not a pre-planned one.
3. **18.28 β Wound-healing rate misattributed:** Line 256 reports 15%β32% as the wound-healing complication rate among mTOR-inhibitor recipients; the cited review gives that range as the incidence after kidney transplantation generally, not the rate on the drug.
4. **18.31 β Two items carry no PubMed link:** "Protein Leakage Into the Urine" (lines 266-270) and "Reproductive and Menstrual Effects" (lines 286-290) are non-Speculative items with no PubMed citation in the annotation or the Magnitude line.
5. **18.22 β "Not quantified" used where figures exist:** Lines 270 and 290 use the "Not quantified in available studies" line although the literature reports ovarian cysts in 20.5% versus 4.9% and a significant proteinuria increase across nine conversion trials.
6. **18.1 β Infection risk omitted:** Increased susceptibility to infection, the drug's boxed warning and an outcome raised in the ER's own cited systematic review, has no item in Potential Risks & Side Effects.
7. **20.2 β No over-the-counter interactions:** Every agent named in Key Interactions & Contraindications is a prescription drug, a food, a supplement or a vaccine; no OTC medicine is listed.
8. **2.12 β Pilot study cited without a link:** The 1 mg daily pilot in healthy older adults is invoked at lines 200 and 248 as a specific study but is never linked anywhere in the ER.
9. **2.10 β Lifespan.io conflict not adjacent:** The Recommended Reading item at lines 61-63 presents Lifespan.io's account of the PEARL trial its own parent nonprofit crowdfunded, without noting that interest at that point; the disclosure appears only at line 150 and in the Conclusion.
## Fixes 28/08/2026 12:47
1. **18.28 β Microbiome subgroup counts corrected:** Changed the PEARL microbiome subgroup composition from "50 women and 31 men" to "31 women and 50 men", matching the published results.
2. **18.27 β Subgroup no longer called pre-planned:** Changed "A pre-planned subgroup" to "An exploratory subgroup", matching the PEARL paper's own description of the samples submitted for gut-microbiome analysis.
3. **18.28 β Wound-healing rate reattributed:** Rewrote the Magnitude line so the 15%β32% range is stated as the incidence of wound-healing surgical complications after kidney transplantation generally, with the review's separate finding of higher frequency on mTOR inhibitors kept as a distinct clause.
4. **18.22 / 18.31 β proteinuria magnitude replaced:** Replaced the "Not quantified in available studies" line with the conversion-meta-analysis finding, its 2,323-patient base, and an explicit statement that no pooled effect figure is reported.
| LINK ADDED: [https://pubmed.ncbi.nlm.nih.gov/25146383/](https://pubmed.ncbi.nlm.nih.gov/25146383/) | tried: β | outcome: supplies the missing PubMed citation for the Protein Leakage Into the Urine item and the direction statement its Magnitude line now carries |
5. **18.22 / 18.31 β reproductive magnitude quantified:** Replaced the "Not quantified in available studies" line with the retrospective-cohort figure of 20.5% versus 4.9% new ovarian cysts, and softened the annotation from "uncontrolled case series with no denominator" to "retrospective and uncontrolled".
| LINK ADDED: [https://pubmed.ncbi.nlm.nih.gov/29087803/](https://pubmed.ncbi.nlm.nih.gov/29087803/) | tried: β | outcome: supplies both the missing PubMed citation and the ovarian-cyst incidence figure for the Reproductive and Menstrual Effects item |
6. **18.1 β Infection risk item added:** Added "Increased Susceptibility to Infection β οΈ Conflicted" under Low with a conflicted-evidence annotation, a net-reading sentence, and a Magnitude line; renamed the Speculative item to "Loss of Cancer Surveillance Over Decades" and dropped its infection clause so the two items no longer share an endpoint.
| LINK ADDED: [https://pubmed.ncbi.nlm.nih.gov/16699448/](https://pubmed.ncbi.nlm.nih.gov/16699448/), [https://pubmed.ncbi.nlm.nih.gov/38310895/](https://pubmed.ncbi.nlm.nih.gov/38310895/) | tried: β | outcome: the two sides of the conflicted infection signal β the cytomegalovirus relative risk of 0.49 and the systematic review's report of more infections in age-related disease |
7. **20.2 β OTC interaction added:** Added a "Over-the-counter acid reducers and painkillers (cimetidine, omeprazole, ibuprofen, naproxen)" bullet giving severity, mechanism, consequence and a substitution, so the section now covers non-prescription medicines.
8. **2.12 β Pilot study now linked:** Linked "the human pilot in older adults" and "the small pilot in healthy older adults at 1 mg daily" to the Kraig et al. 2018 randomized pilot that both sentences describe.
| LINK ADDED: [https://pubmed.ncbi.nlm.nih.gov/29408453/](https://pubmed.ncbi.nlm.nih.gov/29408453/) | tried: β | outcome: the 25-participant 1 mg/day pilot in adults aged 70β95 that reports both the absent cognitive change and the significant hemoglobin and red-cell declines |
9. **2.10 β Lifespan.io interest disclosed at the item:** Rewrote the Recommended Reading annotation to note that the publisher's own nonprofit crowdfunded the trial being summarised, dropping the "gut and dosing caveats" clause to stay inside the 35-word limit.